A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm

Allergan44 enrolled

Overview

This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical practice.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cervical Dystonia Blepharospasm

Interventions

No InterventionOTHER

No treatment (intervention) was administered.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at least 2 years * Treatment with Xeomin® and BOTOX® for at least 2 years each. Exclusion Criteria: * Having a neuromuscular junction transmission disorder or taking any medications that could affect neuromuscular junction transmission * Previous surgical procedure involving bone or muscle for the management of cervical dystonia or blepharospasm.

Locations (2)

Unnamed facility

Colonia Roma Z.P., Mexico

Unnamed facility

Wakefield, United Kingdom

Outcomes

Primary Outcomes

Dose of Botulinum Toxin Used to Treat Cervical Dystonia

Time frame: 4 Years

Dose of Botulinum Toxin Used to Treat Blepharospasm

Time frame: 4 Years

Secondary Outcomes

Botulinum Toxin Inter-injection Intervals

Time frame: 4 Years

Number of Participants with Adverse Events

Time frame: 4 Years

Annual Botulinum Toxin Dose per Patient

Time frame: 4 Years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.